These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27650681)

  • 1. Population pharmacokinetics of exenatide.
    Cirincione B; Mager DE
    Br J Clin Pharmacol; 2017 Mar; 83(3):517-526. PubMed ID: 27650681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.
    Cirincione B; Edwards J; Mager DE
    AAPS J; 2017 Mar; 19(2):487-496. PubMed ID: 27896683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
    J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.
    Li XG; Li L; Zhou X; Chen Y; Ren YP; Zhou TY; Lu W
    Acta Pharmacol Sin; 2012 Nov; 33(11):1379-86. PubMed ID: 22659626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.
    Gao W; Jusko WJ
    Drug Metab Dispos; 2012 May; 40(5):990-7. PubMed ID: 22338110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide pharmacokinetics in healthy Chinese subjects.
    Zhao X; Cui YM; Zhou Y; Zhang HL; Yeo KP; Linnebjerg H; Tham LS; Kothare P; Teng LL; Mace K; Soon D
    Int J Clin Pharmacol Ther; 2008 Sep; 46(9):459-65. PubMed ID: 18793576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Seger M; Wolka AM; Mitchell MI
    Int J Clin Pharmacol Ther; 2011 Feb; 49(2):99-108. PubMed ID: 21255526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
    Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
    Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus
.
    Zang YN; Zhang MJ; Wang YT; Wang C; Wang Q; Zheng QS; Ji LN; Guo W; Fang Y
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):650-658. PubMed ID: 28513427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal impairment on the pharmacokinetics of exenatide.
    Linnebjerg H; Kothare PA; Park S; Mace K; Reddy S; Mitchell M; Lins R
    Br J Clin Pharmacol; 2007 Sep; 64(3):317-27. PubMed ID: 17425627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
    Olsson-Gisleskog P; Jacqmin P; Perez-Ruixo JJ
    Clin Pharmacokinet; 2007; 46(2):159-73. PubMed ID: 17253886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.
    Vlasakakis G; Johnson SL; Lin J; Yao X; Gruenloh CJ; Chism JP; Nunez DJ
    Adv Ther; 2015 Jul; 32(7):650-61. PubMed ID: 26160357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interspecies modeling and prediction of human exenatide pharmacokinetics.
    Chen T; Mager DE; Kagan L
    Pharm Res; 2013 Mar; 30(3):751-60. PubMed ID: 23229855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.
    Li X; Zhao Z; Li L; Zhou T; Lu W
    Drug Deliv; 2015 Jan; 22(1):86-93. PubMed ID: 24467493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
    Gu N; Cho SH; Kim J; Shin D; Seol E; Lee H; Lim KS; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2014 Jan; 36(1):101-14. PubMed ID: 24373998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.
    Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
    Br J Clin Pharmacol; 1999 Jan; 47(1):53-8. PubMed ID: 10073740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
    Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
    Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
    Kolterman OG; Kim DD; Shen L; Ruggles JA; Nielsen LL; Fineman MS; Baron AD
    Am J Health Syst Pharm; 2005 Jan; 62(2):173-81. PubMed ID: 15700891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic model of human insulin following different routes of administration.
    Potocka E; Baughman RA; Derendorf H
    J Clin Pharmacol; 2011 Jul; 51(7):1015-24. PubMed ID: 20940337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of hydroxyurea in cancer patients.
    Tracewell WG; Trump DL; Vaughan WP; Smith DC; Gwilt PR
    Cancer Chemother Pharmacol; 1995; 35(5):417-22. PubMed ID: 7850924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.